Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted Medicare spending per patient per year, reported researchers led by John Mafi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims.. About 6% of Leqembi ...

Assuming conservative lecanemab uptake rates of 1.1-2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth of ...

Change in Alzheimer's Drug Vial Size Could Be Big Money-Saver for Medicare By Dennis Thompson HealthDay Reporter MONDAY, Oct. 14, 2024 (HealthDay News) -- A simple tweak in available vial sizes of ...

“Once opened, our 100mg vial of Tepylute is stable for 14 days when properly stored, ... Both vial sizes are now available, according to Shorla Oncology. This article originally appeared on MPR.

Assuming conservative lecanemab uptake rates of 1.1-2.9% for an estimated 82,000 to 208,000 of eligible people, current vial sizes would lead to an estimated $133 million to $336 million worth of ...

Current vial sizes may result in 5.8% of the Alzheimer's disease drug being thrown away, representing $1,619 in wasted Medicare spending per patient per year, reported researchers led by John Mafi ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions of dollars each year, a new analysis claims. Photo by Adobe Stock ...

Fixed vial sizes for controversial Alzheimer's drug could waste $605 million in Medicare spending each year. Jun 27, 2022. Medicare spending would increase $2.0 to $5.1 billion with lecanemab, ...